/PRNewswire/ TriNetX, through its wholly owned subsidiary TriNetX Oncology GmbH, announces the availability of the European Multiple Myeloma (MM) Real-World.
/PRNewswire/ TriNetX, the global network of healthcare organizations driving real-world research to accelerate the development of new therapies, today.
/PRNewswire/ TriNetX, the global network of healthcare organizations driving real-world research to accelerate the development of new therapies, today.